<http://schema.org/articleBody>
" Pharmaceutical companies hoping to make substantial profits from the development of inhalable insulin treatments for diabetes sufferers may have less of a goldmine on their hands than they believe, it has been claimed.  A report from online market analysis firm Datamonitor published today argues that inhalable insulin treatments are less effective than is widely believed and that they have failed to live up to the high expectations placed upon them by medical experts.  Insulin, used to treat the growing number of cases of diabetes in Britain, has traditionally been administered through an injection, to the dismay of doctors despairing at the deterrent effect this unpleasant form of delivery has on mild sufferers who should begin taking treatment for the disease.  An alternative form of delivery, by inhalation, was lauded by both pharmaceutical companies and medical experts upon its emergence as a possible replacement to injection, but today&amp;#039;s Datamonitor report has been unimpressed with its efficacy.  Referring to the leading inhalable insulin treatment currently available, Dr Daniel Poso, Datamonitor cardiovascular analyst, said: &amp;quot;Presented to great fanfare to physicians and shareholders all over the world as a surefire blockbuster in the making, in Datamonitor&amp;#039;s opinion, Exubera is unlikely to revolutionise insulin therapy as some might expect.&amp;quot;  He added that expected sales of Exubera are likely to stabilise in 2015 rather than continue growth, despite drug companies continuing to develop new, improved alternatives to the current market leader.  &amp;quot;The late-stage insulin pipeline is dominated by non-injectable insulins, and the most advanced preparations in terms of developmental maturity are inhalable formulations,&amp;quot; Dr Poso concluded.  Over 1.8 million people suffer from diabetes in the UK, up from 1.4 million in 1996. \u00A9 Adfero Ltd "^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.netdoctor.co.uk/healthy-living/news/a14404/inhalable-insulin-no-goldmine/>